In previous reports, only 30% of patients with diabetes in the United States on insulin therapy achieved an HbA1c of ≤7.0% (≤53 mmol/mol).4,5 Moreover, in our study, there was a statistically significant, although marginal, reduction in glycemic variability (assessed by measuring the CV of SMBG measurements on multiple, 7-point SMBG profiles over 3 days) with the patch versus pen after 44 weeks. Here, INS is linked to diabetes mellitus.